Literature DB >> 17692647

Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma.

U Baccarani1, E Benzoni, G L Adani, C Avellini, D Lorenzin, M Sainz-Barriga, V Bresadola, A Uzzau, A Risaliti, C A Beltrami, F Bresadola.   

Abstract

The best therapy for hepatocellular carcinoma (HCC) is still debated. Hepatic resection (HR) is the treatment of choice for single HCC in Child A patients, whereas liver transplantation (OLT) is usually reserved for Child B and C patients with multiple nodules. The aim of this study was to compare HR and OLT for HCC within the Milan criteria on an intention-to-treat basis. Forty-eight patients were treated by OLT and 38 by HR. Three- and 5-year patient survival rates were significantly higher (P = .0057) in the OLT group (79% and 74%) than after HR (61% and 26%). The 3- and 5-year disease-free survival rate was better (P = .0005) for OLT (74% and 74%) versus HR (41% and 11%). The probability of HCC recurrences after resection was greater (P = .0002) than after transplantation, achieving 31% and 76% for HR and 2% and 2% for OLT at 3 and 5 years after surgery. The median waiting list time was 118 days; two patients dropped out for HCC progression. We concluded that OLT is superior to HR for small HCC in cirrhotic patients assuming that OLT can be performed within 6 to 10 months after listing to reduce dropouts due to tumor progression.

Entities:  

Mesh:

Year:  2007        PMID: 17692647     DOI: 10.1016/j.transproceed.2007.05.045

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

2.  Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI?

Authors:  N Griffin; H Addley; E Sala; A S Shaw; L A Grant; H Eldaly; S E Davies; T Prevost; G J Alexander; D J Lomas
Journal:  Br J Radiol       Date:  2011-03-08       Impact factor: 3.039

3.  Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy.

Authors:  Ruey-Shyang Soong; Ming-Chin Yu; Kun-Ming Chan; Hong-Shiue Chou; Ting-Jung Wu; Chen-Fang Lee; Tsung-Han Wu; Wei-Chen Lee
Journal:  World J Surg Oncol       Date:  2011-01-27       Impact factor: 2.754

4.  Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.

Authors:  Chao He; Wei Peng; Chuan Li; Tian-Fu Wen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.